IL-1 and IL-1 regulatory pathways in cancer progression and therapy

Alberto Mantovani; Isabella Barajon; Cecilia Garlanda

doi:10.1111/imr.12614

IL-1 and IL-1 regulatory pathways in cancer progression and therapy

Alberto Mantovani, Isabella Barajon, Cecilia Garlanda

Istituto Clinico Humanitas

Research output: Contribution to journal › Review article › peer-review

Abstract

Inflammation is an important component of the tumor microenvironment. IL-1 is an inflammatory cytokine which plays a key role in carcinogenesis and tumor progression. IL-1 is subject to regulation by components of the IL-1 and IL-1 receptor (ILR) families. Negative regulators include a decoy receptor (IL-1R2), receptor antagonists (IL-1Ra), IL-1R8, and anti-inflammatory IL-37. IL-1 acts at different levels in tumor initiation and progression, including driving chronic non-resolving inflammation, tumor angiogenesis, activation of the IL-17 pathway, induction of myeloid-derived suppressor cells (MDSC) and macrophage recruitment, invasion and metastasis. Based on initial clinical results, the translation potential of IL-1 targeting deserves extensive analysis.

Original language	English
Pages (from-to)	57-61
Number of pages	5
Journal	Immunological Reviews
Volume	281
Issue number	1
DOIs	https://doi.org/10.1111/imr.12614
Publication status	Published - Jan 1 2018

Keywords

Inflammation
Inflammation-associated cancer
Interleukin-1
Therapy

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1111/imr.12614

Fingerprint Dive into the research topics of 'IL-1 and IL-1 regulatory pathways in cancer progression and therapy'. Together they form a unique fingerprint.

Cite this

@article{5a6a1f04270c43cfa849ae99350cce1b,

title = "IL-1 and IL-1 regulatory pathways in cancer progression and therapy",

abstract = "Inflammation is an important component of the tumor microenvironment. IL-1 is an inflammatory cytokine which plays a key role in carcinogenesis and tumor progression. IL-1 is subject to regulation by components of the IL-1 and IL-1 receptor (ILR) families. Negative regulators include a decoy receptor (IL-1R2), receptor antagonists (IL-1Ra), IL-1R8, and anti-inflammatory IL-37. IL-1 acts at different levels in tumor initiation and progression, including driving chronic non-resolving inflammation, tumor angiogenesis, activation of the IL-17 pathway, induction of myeloid-derived suppressor cells (MDSC) and macrophage recruitment, invasion and metastasis. Based on initial clinical results, the translation potential of IL-1 targeting deserves extensive analysis.",

keywords = "Inflammation, Inflammation-associated cancer, Interleukin-1, Therapy",

author = "Alberto Mantovani and Isabella Barajon and Cecilia Garlanda",

year = "2018",

month = jan,

day = "1",

doi = "10.1111/imr.12614",

language = "English",

volume = "281",

pages = "57--61",

journal = "Immunological Reviews",

issn = "0105-2896",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - IL-1 and IL-1 regulatory pathways in cancer progression and therapy

AU - Mantovani, Alberto

AU - Barajon, Isabella

AU - Garlanda, Cecilia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Inflammation is an important component of the tumor microenvironment. IL-1 is an inflammatory cytokine which plays a key role in carcinogenesis and tumor progression. IL-1 is subject to regulation by components of the IL-1 and IL-1 receptor (ILR) families. Negative regulators include a decoy receptor (IL-1R2), receptor antagonists (IL-1Ra), IL-1R8, and anti-inflammatory IL-37. IL-1 acts at different levels in tumor initiation and progression, including driving chronic non-resolving inflammation, tumor angiogenesis, activation of the IL-17 pathway, induction of myeloid-derived suppressor cells (MDSC) and macrophage recruitment, invasion and metastasis. Based on initial clinical results, the translation potential of IL-1 targeting deserves extensive analysis.

AB - Inflammation is an important component of the tumor microenvironment. IL-1 is an inflammatory cytokine which plays a key role in carcinogenesis and tumor progression. IL-1 is subject to regulation by components of the IL-1 and IL-1 receptor (ILR) families. Negative regulators include a decoy receptor (IL-1R2), receptor antagonists (IL-1Ra), IL-1R8, and anti-inflammatory IL-37. IL-1 acts at different levels in tumor initiation and progression, including driving chronic non-resolving inflammation, tumor angiogenesis, activation of the IL-17 pathway, induction of myeloid-derived suppressor cells (MDSC) and macrophage recruitment, invasion and metastasis. Based on initial clinical results, the translation potential of IL-1 targeting deserves extensive analysis.

KW - Inflammation

KW - Inflammation-associated cancer

KW - Interleukin-1

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85038006698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038006698&partnerID=8YFLogxK

U2 - 10.1111/imr.12614

DO - 10.1111/imr.12614

M3 - Review article

C2 - 29247996

AN - SCOPUS:85038006698

VL - 281

SP - 57

EP - 61

JO - Immunological Reviews

JF - Immunological Reviews

SN - 0105-2896

IS - 1

ER -

IL-1 and IL-1 regulatory pathways in cancer progression and therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this